Tuhura Biosciences Stock Performance
| HURA Stock | 4.48 0.48 12.00% |
The entity has a beta of -1.05, which indicates a somewhat significant risk relative to the market. As the market becomes more bullish, returns on owning TuHURA Biosciences are expected to decrease slowly. On the other hand, during market turmoil, TuHURA Biosciences is expected to outperform it slightly. TuHURA Biosciences right now has a risk of 11.14%. Please validate TuHURA Biosciences skewness, and the relationship between the treynor ratio and rate of daily change , to decide if TuHURA Biosciences will be following its existing price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days TuHURA Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, TuHURA Biosciences is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return 12 | Five Day Return (10.04) | Year To Date Return (97.70) | Ten Year Return (100.00) | All Time Return (100.00) |
Last Split Factor 1:35 | Last Split Date 2024-10-18 |
1 | Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences - PR Newswire | 10/16/2024 |
2 | TuHURA Biosciences Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC | 10/23/2024 |
3 | Acquisition by Dearborn Dan of 489848 shares of TuHURA Biosciences at 4.94 subject to Rule 16b-3 | 11/12/2024 |
4 | Should You Be Adding Sam-A Pharm To Your Watchlist Today | 11/13/2024 |
5 | TuHURA Biosciences Announces Executive Salary and Stock Options - TipRanks | 11/15/2024 |
6 | Novolog Third Quarter 2024 Earnings EPS 0.023 | 11/22/2024 |
7 | What Tibet AIM Pharm. Inc.s 28 percent Share Price Gain Is Not Telling You | 11/26/2024 |
8 | Hanmi Pharm. Co., Ltd. Stock Has Shown Weakness Lately But Financials Look Strong Should Prospective Shareholders Make The Leap | 12/10/2024 |
9 | HURA Stock Alert Halper Sadeh LLC Is Investigating Whether the Merger of TuHURA Biosciences, Inc. Is Fair to Shareholders | 12/12/2024 |
| Begin Period Cash Flow | 14.3 M | |
| Free Cash Flow | -12 M |
TuHURA |
TuHURA Biosciences Relative Risk vs. Return Landscape
If you would invest 571.00 in TuHURA Biosciences on September 22, 2024 and sell it today you would lose (171.00) from holding TuHURA Biosciences or give up 29.95% of portfolio value over 90 days. TuHURA Biosciences is currently generating 0.0204% in daily expected returns and assumes 11.1368% risk (volatility on return distribution) over the 90 days horizon. In different words, 99% of stocks are less volatile than TuHURA, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
TuHURA Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for TuHURA Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as TuHURA Biosciences, and traders can use it to determine the average amount a TuHURA Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0018
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | HURA |
Estimated Market Risk
| 11.14 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.02 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average TuHURA Biosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of TuHURA Biosciences by adding TuHURA Biosciences to a well-diversified portfolio.
TuHURA Biosciences Fundamentals Growth
TuHURA Stock prices reflect investors' perceptions of the future prospects and financial health of TuHURA Biosciences, and TuHURA Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on TuHURA Stock performance.
| Current Valuation | 173.28 M | ||||
| Shares Outstanding | 26 M | ||||
| Price To Book | 119.45 X | ||||
| EBITDA | (29.12 M) | ||||
| Net Income | (29.32 M) | ||||
| Total Debt | 2.34 M | ||||
| Cash Flow From Operations | (7.18 M) | ||||
| Market Capitalization | 141.65 M | ||||
| Total Asset | 4.36 M | ||||
| Retained Earnings | (88.47 M) | ||||
| Working Capital | 562.42 K | ||||
About TuHURA Biosciences Performance
By analyzing TuHURA Biosciences' fundamental ratios, stakeholders can gain valuable insights into TuHURA Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if TuHURA Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if TuHURA Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (6.72) | (6.39) | |
| Return On Capital Employed | (38.89) | (36.94) | |
| Return On Assets | (6.72) | (6.39) | |
| Return On Equity | 18.81 | 19.75 |
Things to note about TuHURA Biosciences performance evaluation
Checking the ongoing alerts about TuHURA Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for TuHURA Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| TuHURA Biosciences had very high historical volatility over the last 90 days | |
| TuHURA Biosciences has a very high chance of going through financial distress in the upcoming years | |
| TuHURA Biosciences was previously known as Kintara Therapeutics and was traded on NASDAQ Exchange under the symbol KTRA. | |
| Net Loss for the year was (29.32 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| TuHURA Biosciences generates negative cash flow from operations | |
| TuHURA Biosciences has a frail financial position based on the latest SEC disclosures | |
| Latest headline from businesswire.com: HURA Stock Alert Halper Sadeh LLC Is Investigating Whether the Merger of TuHURA Biosciences, Inc. Is Fair to Shareholders |
- Analyzing TuHURA Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether TuHURA Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining TuHURA Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating TuHURA Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of TuHURA Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of TuHURA Biosciences' stock. These opinions can provide insight into TuHURA Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for TuHURA Stock analysis
When running TuHURA Biosciences' price analysis, check to measure TuHURA Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TuHURA Biosciences is operating at the current time. Most of TuHURA Biosciences' value examination focuses on studying past and present price action to predict the probability of TuHURA Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TuHURA Biosciences' price. Additionally, you may evaluate how the addition of TuHURA Biosciences to your portfolios can decrease your overall portfolio volatility.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| CEOs Directory Screen CEOs from public companies around the world | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |